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Premarket assessment of devices for treatment of
critical limb ischemia: The role of Objective
Performance Criteria and Goals
Patrick J. Geraghty, MD,a Jon S. Matsumura, MD,b and Michael S. Conte, MD,c St. Louis, Mo; Madison,
Wis; and San Francisco, Calif
Medical devices are cleared for marketing approval through the Food and Drug Administration (FDA). Unique statutory
requirements, such as the “least burdensome mandate,” have allowed the FDA to employ non-concurrent controls in its
evaluation of prospective therapies. The use of Objective Performance Criteria and Goals (OPC and OPG) for the
premarket evaluation of cardiovascular devices has become established as an alternative to randomized, controlled trials
(RCTs). These single-armed comparisons may facilitate rapid entry of novel devices to the market. Unlike RCTs, they do
not establish superiority or non-inferiority of the examined therapy, and study populations must be carefully inspected
to ensure validity of comparisons to historical controls. ( J Vasc Surg 2009;50:1459-61.)In their accompanying commentary, representatives of
the Food andDrugAdministration (FDA)Center forDevices
andRadiologicalHealth provide a concise overview of current
methods of premarket assessment ofmedical device safety and
efficacy. Kumar et al. note that randomized, controlled trials
(RCTs) provide the highest scientific standard by which the
FDA evaluates the entry of new drugs, devices, or other
therapeutics into the marketplace, yet also acknowledge the
financial, temporal, and subject recruitment challenges that
accompany the design and implementation of RCTs.
The FDA’s approach to regulatory processes is dictated
by the statutory mandate under which the agency operates.
In keeping with its statutory guidance, the FDA does not
require proof of superiority of a proposed device to each
similar existing device or therapy, nor does it seek to
regulate the practice of medicine. Rather, the agency
provides a timely premarket process to assure that pro-
posed medical devices meet reasonable safety and efficacy
benchmarks. Central to the execution of this mission is
the following clause from the FDAModernization Act of
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doi:10.1016/j.jvs.2009.10.0411997: “The Secretary shall consider, in consultation with
the applicant, the least burdensome appropriate means of
evaluating device effectiveness that would have a reason-
able likelihood of resulting in approval.” The “least
burdensome” concept was subsequently defined as a
successful means of addressing a premarket issue that
involves the most appropriate investment of time, effort,
and resources on the part of industry and FDA.1 The
FDA is thus given the leeway to consider alternatives to
randomized, controlled trials, while maintaining sound
scientific practice.
The use of non-concurrent controls in well-defined clini-
cal circumstances has therefore found acceptance within the
regulatory framework of the FDA.2 The cardiac valve litera-
ture demonstrates the successful adaptation of historical data-
sets to formulate Objective Performance Criteria (OPC) for
new devices.3 Established OPC permit comparison of new
devices to validated historical controls in single-armed trials,
and thus expedite the entry of innovative devices into the
medical arena.Whenhistoric controls are less robust in nature,
or are gathered from alternate treatment methodologies, Ob-
jective Performance Goals (OPGs) may be suggested, and
developed intoOPC as the supporting dataset is strengthened
over time.4
Lastly, not all data collection occurs prior to marketing
approval. Postmarket data collection provides valuable in-
formation regarding long-term outcomes, and may reveal
unanticipated complications or late events that require
further analysis.
DEFINING PERFORMANCE GOALS FOR
CRITICAL LIMB ISCHEMIA
Critical limb ischemia (CLI) is a complex process,
anatomically multilevel in nature, which affects several dis-
tinct high-risk subpopulations. The number, morphology,
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CLI patients may differ dramatically from patient to pa-
tient.Moving from the traditional arterial-segmentmarket-
ing approval to disease-state marketing approval places a
stronger focus on patient-centered outcomes (survival,
limb salvage, and burden of reinterventions) without aban-
doning the traditional surgical focus on patency of the
treated vessel. The accompanying manuscript by Conte et
al. summarizes the recommendations of the Society for
Vascular Surgery (SVS) Working Group on performance
goals for CLI. As noted previously, promulgation of these
performance goals aims to benefit patients by providing a
timely and cost-effective means of device evaluation. It is
hoped that these goals will also be useful for the evaluation
of non-implanted devices for CLI intervention, and bio-
logic therapeutics for CLI treatment.
In addition to the patient benefits summarized
above, avoidance of the expense and time required for
randomized studies provides a clear financial incentive
for medical device manufacturers to pursue single-armed
trials. However, adoption of the OPG format is not
without risk. Among the real-world concerns of the
authors is that single-armed trials may allow subtle bias
in patient selection to mask treatment futility. The “clin-
ical high-risk (age over 80/tissue loss)” subgroup in the
accompanying article represents a population that may
well benefit from endovascular treatment. However, if
investigators shy away from enrolling those patients with
more substantial degrees of tissue loss (eg, Rutherford
stage 6), the resulting cohort will outperform expecta-
tions, thus potentially validating a device that would not
have demonstrated noninferiority in a randomized, con-
trolled trial format. Therefore, ongoing collaborative
efforts will focus on formulating a statistically valid ap-
proach to risk-adjusting the OPG targets for a given trial,
based on characteristics of the enrolled study population.
Post-enrollment adjustment of performance goals would
enable future study sponsors to recruit reasonably heter-
ogenous study populations, and yet still qualify for com-
parison to the historical surgical controls.
Accumulation of robust outcomes data for angioplasty-
based CLI treatment should remain a priority. The ac-
companying SVS Working Group manuscript offers de-
tailed recommendations for standardized trial design and
outcomes assessment. Utilizing these guidelines, compi-
lation of high-quality angioplasty data may yet be accom-
plished, and may permit development of complemen-
tary, angioplasty-based performance goals for CLI
treatment. The OPG suggested by the SVS Working
Group should be viewed as a starting point, with the
expectation of further refinement over time by the accu-
mulation of additional data from CLI trials.
DIFFERENTIATING PERFORMANCE GOALS
FROM PRACTICE GUIDELINES
The proposed performance goals for CLI devices are
the product of an intensive analysis of available historic
controls from published randomized controlled trials. Al-though the resultant OPGs are based upon rigorous statis-
tical evaluation, it is crucial that they not be mistaken for
practice guidelines. The narrowly defined constructs of
performance goals exist solely for the facilitation of medical
device approval. Attainment of the OPG standards implies
that an acceptable level of device safety and efficacy has
been demonstrated, and thus permits introduction of the
candidate device into the realm of clinical usage. It remains
for robust clinical investigation, including RCTs, to subse-
quently provide appropriate scientific evidence to guide
clinical decision-making and appropriate utilization.
In contrast to the carefully limited function of perfor-
mance goals, practice guidelines seek to bring a data-driven
sensibility to the expansive clinical scope of modern vascu-
lar surgery. The Society for Vascular Surgery maintains
several committees charged with the exposition of practice
guidelines for a variety of topics, such as thoracic aortic
disease, infrarenal aortoiliac aneurysmal disease, lower ex-
tremity arterial disease, arterio-venous hemodialysis access,
and venous disease. These writing groups evaluate the
broad range of available clinical literature on the topic of
interest, and aid the practicing surgeon by refining that
evidence into succinct recommendations for clinical care.
Strength of clinical recommendations and quality of the
supporting evidence are graded on a standardized scale,
with recognition that many areas will require further re-
search before definitive clinical guidance can be provided.
CONCLUSION
The FDA plays a critical role in premarket assessment
and approval of new medical devices, yet physician and
societal participation in this process remains essential.
Working in consultation with members of the FDA, the
CLI Performance Goals Task Force has provided a carefully
validated set of safety and efficacy criteria for evaluation of
new treatment modalities. Broad adoption of the accompa-
nying recommendations for CLI trial design will facilitate
data sharing between investigator groups, and contribute
to the periodic refinement of these performance criteria.
OPC and OPG do not supplant the role of properly
conducted RCT in discerning superiority between different
therapies, and should not be misinterpreted as practice
recommendations. Although the FDA, by statute, does not
consider cost of medical devices, this factor looms large in
the deliberations of the Agency for Healthcare Research
and Quality, the Centers for Medicare and Medicaid Ser-
vices, private payers, and practicing physicians and sur-
geons. These entities may require a more rigorous proof of
efficacy than that offered by single-armed comparisons.
Moreover, the scope and emphasis of FDA device scrutiny,
although defined by statute, remains open to reasoned
debate. How shall we assess the safety and efficacy of
combined pharmacologic and mechanical interventions?
Combined biologic and mechanical interventions? Ongo-
ing collaboration between the FDA, industry, and practic-
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tion for the benefit of all patients.
AUTHOR CONTRIBUTIONS
Conception and design: PG, JM, MC
Analysis and interpretation: PG, JM, MC
Data collection: N/A
Writing the article: PG, JM, MC
Critical revision of the article: PG, JM, MC
Final approval of the article: PG, JM, MC
Statistical analysis: N/A
Obtained funding: N/A
Overall responsibility: PGREFERENCES
1. The Least Burdensome Provisions of the FDA Modernization Act of 1997:
Concept and Principles; Final Guidance for FDA and Industry. Available at
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/
GuidanceDocuments/ucm085994.htm. Accessed June 15, 2009.
2. Chen E, Sapirstein W, Ahn C, Swain J, Zuckerman B. FDA perspective
on clinical trial design for cardiovascular devices. Ann Thorac Surg
2006;82:773-5.
3. Grunkemeier GL, Jin R, Starr A. Prosthetic heart valves: Objective
Performance Criteria versus randomized clinical trial. Ann Thorac Surg
2006;82:776-80.
4. Goode J, Sapirstein W, Zuckerman B. FDA perspective on clinical trial
design for femoropopliteal stent correction of peripheral vascular insuffi-
ciency cardiovascular devices. Catheter Cardiovasc Interv 2007;69:920-1.Submitted Sep 18, 2009; accepted Oct 12, 2009.
